Advertisement

Topics

Daiichi Sankyo, ArQule’s Tivantinib Misses Primary Endpoint in Late-Stage Liver Cancer Trial

09:49 EST 17 Feb 2017 | Speciality Pharma Journal

BURLINGTON, Mass., TOKYO, MUNICH, & PARSIPPANY, N.J.–(BUSINESS WIRE)–ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo today announced that the METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma (HCC) did not meet its primary endpoint of improving overall survival. METIV-HCC is a biomarker-selected, double-blind, placebo-controlled, randomized phase 3 study evaluating tivantinib (2:1) versus best supportive care …

Original Article: Daiichi Sankyo, ArQule’s Tivantinib Misses Primary Endpoint in Late-Stage Liver Cancer Trial

NEXT ARTICLE

More From BioPortfolio on "Daiichi Sankyo, ArQule’s Tivantinib Misses Primary Endpoint in Late-Stage Liver Cancer Trial"

Quick Search
Advertisement